Brian Abrahams
Analyst at RBC Capital
Ticker Coverage
Sector Coverage
Mentions in the News
Here's why Gilead should buy a key asset from Celgene, as long as it can strike a deal for less than $9.6 billion
Bristol-Meyers Squibb struck a $74 billion deal in January to acquire the drug company Celgene. To get regulators to sign off on the deal, Celgene plans to divest an anti-inflammatory drug called Otezla. Wall Street analysts are trying to figure out which pha…
Published: Jul 19 2019
Gilead Ups Stake In Galapagos With $5B Deal to Jumpstart Its R&D
Gilead Sciences on Sunday looked to another firm to rejuvenate its research capabilities, agreeing to put more than $5 billion in cash into Galapagos NV and get access to a slew of experimental drugs in return. Gilead (NASDAQ: GILD) will pay Galapagos (NAS…
Published: Jul 15 2019
GSK touts new Dovato switching data. Is it enough to shake Gilead's HIV lead?
GlaxoSmithKline’s ViiV Healthcare already boasts an approval for Dovato, a two-drug HIV regimen, in newly diagnosed patients. And it just added some new data that aims to at least draw level with market leader Gilead in already-treated patients.
Published: Jul 10 2019
Show More..
Would you like to be included in the directory? Let us know!
© Street Contxt. All Rights Reserved.